A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OHAs / oral hypoglycemic agents

[Related PubMed/MEDLINE]
Total Number of Papers: 148
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OHAs  (>> Co-occurring Abbreviation)
Long Form:   oral hypoglycemic agents
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Adherence to self-monitoring of blood glucose in Chinese patients with type 2 diabetes: current status and influential factors based on electronic questionnaires. CDS, IMB, SMBG, T2DM
2019 Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure? CIN, CT
2019 Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population. FBG, HMC, T2DM
2019 Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes. FPG, T2DM
2019 Maternal and neonatal outcomes following a diabetic pregnancy within the context of HIV. BMI, PNM
2019 Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. ---
2019 Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study. CKD, DPP-4i, HHF, MACE
2019 Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine. ADMA, MG-H1
2019 The Association Between Insulin Initiation and Adverse Outcomes After Hospital Discharge in Older Adults: a Population-Based Cohort Study. aHR, CI, ED
10  2019 The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial. HOMA
11  2019 Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients. LMT, PEDF, TBR
12  2018 A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats. DM, SD, STZ
13  2018 A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes. CSII, FPG, MAGE
14  2018 Adherence of patients with type 2 diabetes mellitus to medications: the role of risk preferences. OR, PDC
15  2018 An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus. DM, QOL, QOLID
16  2018 Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control. ---
17  2018 Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study). alpha-GI, BG, DPP-4, OHA-Q, SU
18  2018 Elements of the Veterans Health Administration Patient-Centered Medical Home are Associated with Greater Adherence to Oral Hypoglycemic Agents in Patients with Diabetes. MPRs, PCMH, VHA
19  2018 Insulin degrading enzyme is up-regulated in pancreatic beta cells by insulin treatment. HFD, IDE
20  2018 Medication adherence among patients with Type 2 diabetes: A mixed methods study. OR
21  2017 A simple dietary addition of fenugreek seed leads to the reduction in blood glucose levels: A parallel group, randomized single-blind trial. ---
22  2017 Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. CIs, OR, OR, T2DM
23  2017 Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100mg versus 300mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. AEs, CIs, OR, RCTs, T2DM
24  2017 Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. KDA, T2DM
25  2017 Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. KDA, T2DM
26  2017 Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies. PUFA
27  2017 Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. AG, AUC, MAGE
28  2017 Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea. ---
29  2017 Diabetes Drug Prescription Pattern and Awareness Among Health Care Providers in Sub-Himalayan Region of India: A Population Based Study. SU
30  2017 Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. TB-DM
31  2017 Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents. GWG, T2DM
32  2017 How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing. GDR, LIS
33  2017 Impact of formulary restrictions on medication use and costs. GDR, LIS, PDC, RAS
34  2017 Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan. CKD, DM
35  2017 Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. DM, MACEs
36  2017 Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. ---
37  2017 Reported hypoglycemia in Type 2 diabetes mellitus patients: Prevalence and practices-a hospital-based study. OP
38  2017 Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review. FDCs, T2DM
39  2017 Use of pharmacy dispensing data to measure adherence and identify nonadherence with oral hypoglycemic agents. MRAP80, PDC
40  2016 Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa. CI, DGH, DME, DR, OR, PDR, T2DM
41  2016 Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. CI, HCC, HRs, T2DM
42  2016 Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes. Group IA, PCGR, T2D
43  2016 Chronic kidney disease stages among diabetes patients in the Cape Coast Metropolis. CKD, CKD-EPI, eGFR, KDIGO
44  2016 Effectiveness of Minimally Invasive Hybrid Surgery for Ileal Interposition (MIHSII) for the Resolution of Type 2 Diabetes. BMI, MIHSII
45  2016 Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. CVDs, RCTs, RRs, T2D
46  2016 Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. ---
47  2016 The Impact of Patient-Centered Medical Homes on Quality of Care and Medication Adherence in Patients with Diabetes Mellitus. MPR, OR, PCMHs
48  2015 Durability of oral hypoglycemic agents in drug naive patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). NDR, SU, T2DM
49  2015 Effects of oral hypoglycemic agents on platelet function. ---
50  2015 Factors Associated with Glycemic Variability in Patients with Type 2 Diabetes: Focus on Oral Hypoglycemic Agents and Cardiovascular Risk Factors. ASCVD, GV, MAG, SD, SUs, T2DM
51  2015 Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. DPP-4, DSME, SUs
52  2015 Ileal interposition surgery for treatment of type 2 diabetes mellitus-pros and cons. ---
53  2015 Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes. IABs, IQR, IRI
54  2015 Insulin Initiation in Insulin-Naive Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study. MOTIV, T2DM
55  2015 Medication type modifies inflammatory response to traffic exposure in a population with type 2 diabetes. ---
56  2015 Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. BI, ORBIT, ORBIT
57  2015 Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. CVD, Hb, T2DM
58  2015 Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. DiabMedSat, HRQL, OHA-Q, PRO, PROQOLID, T2DM
59  2015 Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan. DPP-4i, SU, T2DM
60  2015 [Fixed-dose combination]. FDC, T2DM
61  2014 A pilot study of add-on oral hypoglycemic agents in treatment-naive genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. CHC, IR, PR, SVR
62  2014 A systematic literature review of methodologies used to assess medication adherence in patients with diabetes. MEMS, MPRs
63  2014 Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes. ---
64  2014 Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs. EASD, T2DM
65  2014 Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. GCK
66  2014 Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey. KNHANES
67  2014 Current status of prescription in type 2 diabetic patients from general hospitals in busan. ---
68  2014 Estimating the Impact of Oral Diabetes Medication Adherence on Medical Costs in VA. FY, IVs, MPR, VA
69  2014 Factors affecting medication adherence: patient perspectives from five veterans affairs facilities. VA
70  2014 HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. apoA-I, FIELD, HDL-C, HOMA-B, HR
71  2014 Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study. CGM
72  2014 Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. DPP-4, GIP, GLP-1
73  2013 Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study. BMI, SOLVE
74  2013 Medication adherence to oral hypoglycemic agents among type II diabetic patients and their clinical outcomes with special reference to fasting blood glucose and glycosylated hemoglobin levels. FBG
75  2013 The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. ---
76  2013 Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. LADA
77  2012 Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? AUCs
78  2012 Does the presence of a pharmacist in primary care clinics improve diabetes medication adherence? FTEs, MPRs
79  2012 Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. CVD, eGFR
80  2012 Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes. DSG, T2DM
81  2012 Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. BMI, DM, SG
82  2012 Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. DSG
83  2012 Pharmacoepidemiological profiles of oral hypoglycemic agents among 28,773 Chinese patients with diabetes. AOR
84  2012 Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. AGEs, FDG-PET, TBR
85  2012 Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. QOL
86  2012 The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. BMI, HbA1c
87  2012 Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. HF, MI
88  2011 Adherence to oral hypoglycemic agents in 26,782 Chinese patients: a cohort study. AOR, CI, MPR
89  2011 Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. HR, JPAD
90  2011 Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study. NPY, T2DM
91  2011 Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. BG, T2DM
92  2011 Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus. ITAS
93  2011 Gestational diabetes mellitus: Non-insulin management. GDM
94  2011 Long-term glycaemic outcome of structured nurse-led diabetes care in rural Africa. BMI
95  2011 Oral hypoglycemic agents for gestational diabetes mellitus? GDM
96  2011 The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. MG
97  2010 New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). CHD, CVD, HbA1c, NDR
98  2010 Oral hypoglycaemics - a review of the evidence. ---
99  2010 Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. CI, OR, WMD
100  2010 Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer. ---